{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:13Z","timestamp":1790641573762,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting\/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.<\/jats:p>","DOI":"10.3390\/ijms262010070","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:17:02Z","timestamp":1760617022000},"page":"10070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-2594","authenticated-orcid":false,"given":"Beata","family":"Kaleta","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41423-020-00626-z","article-title":"Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity","volume":"18","author":"Sogkas","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Huang, S.U., Kulatunge, O., and O\u2019Sullivan, K.M. (2023). Deciphering the Genetic Code of Autoimmune Kidney Diseases. Genes, 14.","DOI":"10.3390\/genes14051028"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Vaglio, A., Gattorno, M., McAdoo, S., Obici, L.P., and Ghiggeri, G.M. (2023). Editorial: The kidney in auto-immune and auto-inflammatory processes: Definitions, mechanisms, and biomarkers. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1129021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.13119","article-title":"The role of the immune system in kidney disease","volume":"192","author":"Tecklenborg","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Martin, C.E., and Jones, N. (2018). Nephrin Signaling in the Podocyte: An Updated View of Signal Regulation at the Slit Diaphragm and Beyond. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00302"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc2410840","article-title":"Autoantibodies Targeting Nephrin in Podocytopathies","volume":"391","author":"Bruschi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2017.34","article-title":"T cells and autoimmune kidney disease","volume":"13","author":"Bradley","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.ajkd.2021.07.019","article-title":"Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review","volume":"79","author":"Kant","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/eji.201847517","article-title":"Plasma cells: The programming of an antibody-secreting machine","volume":"49","author":"Tellier","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/TP.0000000000004038","article-title":"DAMPs Released From Injured Renal Tubular Epithelial Cells Activate Innate Immune Signals in Healthy Renal Tubular Epithelial Cells","volume":"106","author":"DeWolf","year":"2022","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110307","DOI":"10.1016\/j.intimp.2023.110307","article-title":"The role of IL-17 in acute kidney injury","volume":"119","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molmed.2010.06.002","article-title":"Neutrophils: Game changers in glomerulonephritis?","volume":"16","author":"Mayadas","year":"2010","journal-title":"Trends Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Turner, J.E., Rickassel, C., Healy, H., and Kassianos, A.J. (2019). Natural Killer Cells in Kidney Health and Disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00587"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2022.22.e6","article-title":"CAR T Cell Immunotherapy Beyond Haematological Malignancy","volume":"22","author":"Hupperetz","year":"2022","journal-title":"Immune Netw."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12026-021-09236-x","article-title":"Chimeric antigen receptor (CAR) immunotherapy: Basic principles, current advances, and future prospects in neuro-oncology","volume":"69","author":"Yoo","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00005-023-00683-y","article-title":"In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy","volume":"71","author":"Wojciechowska","year":"2023","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., and Zhou, D. (2023). Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers, 15.","DOI":"10.3390\/cancers15133476"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hiltensperger, M., and Krackhardt, A.M. (2023). Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1121030"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102240","DOI":"10.1016\/j.xcrm.2025.102240","article-title":"CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review","volume":"6","author":"Knoedler","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Waghela","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103257","DOI":"10.1016\/j.autrev.2022.103257","article-title":"Research advances on targeted-Treg therapies on immune-mediated kidney diseases","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ndt\/gfad265","article-title":"The new generation of B cell-targeting therapies for the treatment of autoimmune kidney diseases","volume":"39","author":"Trivioli","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chen, Z., Xu, Q., and Shou, Z. (2024). Application of CD38 monoclonal antibody in kidney disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1382977"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Muto, M., Suzuki, H., and Suzuki, Y. (2024). New Insights and Future Perspectives of APRIL in IgA Nephropathy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910340"},{"key":"ref_31","first-page":"e20440","article-title":"Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis","volume":"13","author":"Shrestha","year":"2021","journal-title":"Cureus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","article-title":"Targeting APRIL in the treatment of glomerular diseases","volume":"106","author":"Cheung","year":"2024","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMoa2305635","article-title":"Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL?","volume":"2018","author":"Pulsipher","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4161\/onci.20592","article-title":"A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)","volume":"1","author":"Stone","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","article-title":"Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: A comprehensive review","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Bull."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dimitrov, K., Merkle, F., Dimitrov, M., Merkle, S., Hoover, A., and Bachanova, V. (2025). Major Adverse Events with Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation. Ann. Emerg. Med.","DOI":"10.1016\/j.annemergmed.2025.07.005"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","article-title":"Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies","volume":"104","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"sfae359","DOI":"10.1093\/ckj\/sfae359","article-title":"Acute kidney injury following CAR-T cell therapy: A nephrologist\u2019s perspective","volume":"18","author":"Kanbay","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103369","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J. Autoimmun."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, H., Tang, L., Kong, Y., Liu, W., Zhu, X., and You, Y. (2023). Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119115"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:24:03Z","timestamp":1760617443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":56,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms262010070"],"URL":"https:\/\/doi.org\/10.3390\/ijms262010070","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}